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ABSTRACT 25 
The human genome displays a rich fossil record of past gamma-retrovirus infections, yet no 26 
current epidemic is evident, despite environmental exposure to viruses that infect human 27 
cells in vitro. Feline leukemia viruses (FeLVs) rank high on this list, but domestic or 28 
workplace exposure has not been associated with detectable serological responses. Non-29 
specific inactivation of gamma-retroviruses by serum factors appears insufficient to explain 30 
these observations. To investigate further we explored the susceptibility of primary and 31 
established human cell lines to FeLV-B, the most likely zoonotic variant. Fully permissive 32 
infection was common in cancer-derived cell lines, but was also a feature of non-33 
transformed keratinocytes and lung fibroblasts.  Cells of haematopoietic origin were less 34 
generally permissive and formed discrete groups on the basis of high or low intracellular 35 
protein expression and virion release. Potent repression was observed in primary human 36 
blood mononuclear cells and a subset of leukemia cell lines. However, the early steps of 37 
reverse transcription and integration appear to be unimpaired in non-permissive cells.  38 
FeLV-B was subject to G->A hypermutation with a predominant APOBEC3G signature in 39 
partially permissive cells but was not mutated in permissive cells or in non-permissive cells 40 
that block secondary viral spread. Distinct cellular barriers that protect primary human 41 
blood cells are likely to be important in protection against zoonotic infection with FeLV.  42 
215 words 43 
 44 
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IMPORTANCE 46 
Domestic exposure to gamma-retroviruses such as feline leukemia viruses (FeLV) occurs 47 
worldwide but the basis of human resistance to infection remains incompletely understood. 48 
The potential threat is evident from the human genome sequence which reveals many past 49 
epidemics of gamma-retrovirus infection and from recent cross-species jumps of gamma-50 
retroviruses from rodents to primates and marsupials. This study examined resistance to 51 
infection at the cellular level with the most prevalent human cell-tropic FeLV variant, FeLV-52 
B.  We found that blood cells are uniquely resistant to infection with FeLV-B due to the 53 
activity of cellular enzymes that mutate the viral genome. A second block was identified that 54 
appears to suppress viral gene expression after the viral genome has integrated into the 55 
host cell genome.  As cells derived from other normal human cell types are fully supportive 56 
of FeLV replication, innate resistance of blood cells could be critical in protecting against 57 
cross-species infection.   58 
148 words 59 
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 INTRODUCTION 63 
Completion of the draft human genome sequence in 2001 revealed that a remarkable ~8% 64 
of the genome consists of retrovirus-like elements (1).  Although elements found to date are 65 
replication-defective, many are related to gamma-retroviruses currently circulating as 66 
infectious agents in a range of mammalian and avian species (2). Moreover, the capacity of 67 
gamma-retroviruses to cross-species boundaries is clear from the fossil record of 68 
endogenous viruses, and from evidence of recent jumps across wide species barriers from 69 
rodents to primates and marsupials of gibbon ape leukemia virus (GaLV) and koala 70 
retrovirus (KoRV) respectively (3-5). 71 
The ability of some variants of feline leukemia virus (FeLV), a feline gamma-retrovirus, to 72 
replicate to high titre in human cells in vitro is a long-standing observation that led to early 73 
concerns with regard to zoonotic spread (6, 7).  FeLVs represent important pathogens of the 74 
domestic cat that are capable of cross-species spread to endangered feline species (8, 9). 75 
Despite widespread domestic contact with FeLV-infected cats which can shed virus in saliva 76 
and other body fluids, a series of careful studies showed no evidence of serological 77 
responses in exposed individuals (10). Human serum factors that lyse or inactivate gamma 78 
retroviruses (11, 12) offer a significant obstacle to cross-species spread, but appear 79 
insufficient to account fully for resistance as sensitivity can be attenuated in viruses released 80 
by human cells after initial cell-cell spread (13).  81 
Our recent interest in the replication of FeLV in human cells was fuelled by the desire to use 82 
these agents as insertional mutagens and gene discovery tools in human cancer cells in a 83 
manner similar to murine leukemia viruses (MLVs) in their  natural host (14, 15).  In support 84 
of this goal, the ability of FeLV to integrate preferentially at strong promoters and enhancers 85 
is also manifested in human cells infected in vitro (16). However, it became apparent from 86 
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our initial studies that resistance of human cells to FeLV at the cellular level is a multifaceted 87 
phenomenon that is likely to be relevant to cross-species transfer, motivating us to conduct 88 
a deeper study. 89 
FeLVs comprise a family of viruses that frequently occur as phenotypic mixtures in infected 90 
cats (17, 18).  Three major subgroups have been described that use different receptors to 91 
enter feline host cells (17).  Virtually all natural isolates contain a subgroup A FeLV 92 
component that enters via the thiamine transporter THTR1 (19). This is the major 93 
horizontally transmitted form of FeLV in cats but has been considered unlikely to be 94 
zoonotic due to its low affinity for the human receptor homologue hTHTR1 (19). Many field 95 
isolates of FeLV consist of a mixture of FeLV-A and B, the latter arising by recombination and 96 
acquisition of envelope gene sequences from endogenous FeLV-related sequences (20). 97 
FeLV-B isolates can replicate efficiently in at least some cultured human cells without 98 
cytopathic effect (6, 7, 17).  Moreover, FeLV-B strains enter via the widely expressed 99 
phosphate transporter Pit-1 and/or the related Pit-2 (21). Another human cell-tropic variant 100 
type is FeLV-C, which is generated by mutation of the receptor-binding domain of Env (22) 101 
facilitating entry through heme transporters FLVCR1 or FLVCR2 (23, 24). However, FeLV-C 102 
isolates are rare in nature (~1% of isolates) (17) and presumably short-lived due to their 103 
propensity to induce rapidly fatal aplastic anemia (25). A further FeLV envelope variant that 104 
has been described is the potently immunosuppressive FeLV-T, but this is also acutely 105 
pathogenic and is stringently host-specific as its complex entry requirements include a 106 
truncated envelope protein derived from endogenous FeLV-related proviruses that is 107 
released by normal feline lymphoid cells (26, 27). Taken together, these biological 108 
properties implicate FeLV-B strains as the most likely candidates for zoonotic spread.  109 
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While the study of HIV and other primate lentiviruses has identified many factors that 110 
control host range by restricting replication (28), the gamma-retroviruses have been less 111 
well studied in this regard. MLVs have been shown to be highly sensitive to human APOBEC3 112 
cytidine deaminase activity while able to evade murine APOBEC3 (29, 30). The effects of 113 
human APOBEC3 activity on FeLV have not been reported, although the remarkable 114 
sequence stability of the common transmitted form of FeLV in the domestic cat and its low 115 
mutation rate on infection of other felids strongly suggests that it has evolved to evade 116 
feline APOBEC activity (31, 32).  117 
This study confirms FeLV-B as the most likely variant to have zoonotic potential, as virtually 118 
all human cells are susceptible with only limited post-entry barriers to infection.  Resistance 119 
of primary blood cells at a post-integration step along with potent APOBEC3 mutation of 120 
virions released from haematopoietic cells appear to be significant factors in limiting 121 
infectivity for human cells. The possibility that FeLV could in future evolve to evade these 122 
barriers cannot be discounted. 123 
  124 
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MATERIALS AND METHODS 125 
Virus stocks 126 
FeLV-B stocks were generated by transfection of an infectious molecular clone (pFGB) (33) 127 
and propagation in the feline fibroblast cell line AH927 or HEK human embryonic kidney 128 
cells as described (34). For FeLV-A stocks, HEK293 cells were transfected with pFGA-5 (20) to 129 
avoid possible recombination and generation of FeLV-B (35). FeLV infectivity was 130 
determined by titration on S+L- QN10 cells (36). 131 
Cells 132 
Cells lines were derived from curated frozen stocks maintained in our laboratory (Jurkat, 133 
K562, CEM, Reh, Kasumi, U937, MCF-7) or by colleagues in the Glasgow Cancer Research UK 134 
Centre, including  Prof A. Biankin (pancreatic cancer TKCC series) and Prof T. Holyoake 135 
(chronic myeloid leukemia lines KYO-1, BV173, KU812, LAMA84, EM-2; B-cell acute 136 
lymphoblastic leukemia lines ALL/MIK, TOM-1). IMR90 fibroblasts were provided by Prof P. 137 
Adams (37), while EBV-transformed lymphoblastoid cell lines (LCLs) were obtained from 138 
Prof R Jarrett.  CEMSS cells were kindly provided by Prof M. Malim (King’s College, London). 139 
CD34+ cells were purified by positive selection using anti-CD34 conjugated magnetic 140 
microbeads (Miltenyi Biotec Inc #130-046-703) from cord blood samples generously 141 
provided by the Children’s Cancer and Leukaemia Group (CCLG). Primary blood 142 
mononuclear cells were obtained from Cambridge Bioscience (1 sample) and the Scottish 143 
National Blood Transfusion Service (3 samples).   144 
Dilution /spreading assay and Southern blot analysis 145 
4 x 105  KyoI , Reh cells or  5 x 104 HEK293 cells were plated  per well in 6 wells of a 12 well 146 
plate the day before infection.  FeLV-B virus  was harvested from sub-confluent virus 147 
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producing  HEK293 cells, filtered through 0.45μM filter and serially diluted 1 in 10 in RPMI 148 
1640 10% FCS.  0.5ml of filtered virus dilution was added per well, or medium alone to 149 
control well, for 2 hours.  Cells were then fed with fresh medium and expanded as normal 150 
for 14 days. Genomic DNA was extracted from PBS washed, pelleted cells using Qiagen 151 
DNeasy Blood and Tissue Kit. 15μg aliquots of genomic DNA were digested overnight with 152 
KpnI, separated on 0.8% agarose TAE gel , transferred onto Hybond N (Amersham) in 20xSSC  153 
and hybridised to FeLV ExU3 as previously described (21).  154 
Quantitative real time RT-PCR 155 
RNA was extracted from cultured cells using Qiagen RNeasy mini kit and  cDNA synthesised 156 
from 1μg RNA using Qiagen QuantiTect Reverse Transcription kit. 12.5ng aliquots of cDNA 157 
were amplified in triplicate using Power SYBR green PCR master mix (Thermo Fisher 158 
Scientific) and Qiagen QuantiTect primer assays for human HPRT (QT00059066), APOBEC3G 159 
(QT00070770), SLC20A1 (PIT-1) (QT00028763) or SLC19A2 (THTR1) (QT00007847)  on an  160 
ABI 7500 Real Time PCR System. Quantification was carried out relative to HEK293 cells and 161 
normalized to HPRT expression. 162 
Semi-quantitative DNA PCR 163 
100ng aliquots of genomic DNA was amplified in Reddy Mix (Thermo Fisher Scientific) using 164 
primers for FeLV envA F 5’-TAAAACACGGGGCACGTTAC-3’ and R 5’-165 
GGAGGTGGGCTTCCACCAAG-3’;  FeLV envB F 5’-ATGTGATCAGCCTATGAGGA-3’ and R5’-166 
CACTAGCTCCCGTTGTCGAG-3’;  FeLV LTR F 5’- TAGCTGAAA CAGCAGAAGTTTCAAG-3’and R 167 
5’-GGAAGGTCGAACTCTGGTCAAC-3’ ; and Myc F 5’-CCAACAGGAACTATGACCTCG-3 and R 5’-168 
GTAGAAGTTCTCCTCCTCGTC-3’. Samples were denatured at 94oC for 3mins then subjected 169 
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to 35 cycles of  94oC 30s, 60oC 30s, 72oC 30s. Amplification products were separated by 170 
electrophoresis on 2% agarose TAE gels and visualised by ethidium bromide staining. 171 
DNA qPCR 172 
Genomic DNA was extracted by Qiagen DNeasy mini kit and 20ng aliquots were amplified 173 
using primers for human β2microglobulin F 5’-GGAATTGATTTGGGAGAGCAT-3’ and R 5’-174 
CAGGTCCTGGCTCTACAATTTACTAA-3’, FeLV U3-LTR F 5’-TAGCTGAAA CAGCAGAAGTTTCAAG-175 
3’ and R 5’-GGAAGGTCGAACTCTGGTCAAC-3’,  envB F 5’CGGTATCCCGGCAAGTAATG-3’  and 176 
R 5’-GGTTTTTGATCAGGCAGGACTAGA-3’ in Power SYBR green PCR master mix and detected 177 
on an  ABI 7500 Real-Time PCR System.  Samples were normalized to β2microglobulin.  178 
Western blots 179 
PBS washed, pelleted cells  were lysed in whole cell lysis buffer and protein concentration 180 
measured by Bio-Rad protein assay. Virion lysates were prepared from 2ml pre-cleared 181 
virion supernatant by centrifugation in a Beckman TL100 benchtop ultracentrifuge for 2hrs 182 
at 37000rpm at 4oC. Virion pellets were resuspended in 75μl lysis buffer and an equal 183 
volume (13μl) of virion protein, or 10μg aliquots of cellular protein, was separated on 4-12% 184 
NuPAGE Novex Bis-Tris  gel in NuPAGE MOPS SDS buffer and transferred to Hybond ECL 185 
(Amersham) in NuPAGE transfer buffer. Following overnight blocking in 5%milk in TBST the 186 
filter was exposed to a 1:500 dilution of αp27gag monoclonal antibody (VPG19.1 gift of 187 
Brian Willett) and detected by ECL detection reagent (GE Healthcare) 188 
Hypermutation analysis 189 
FeLV gag or pol fragments were generated by amplification of 100ng aliquots of infected cell 190 
genomic DNA in Reddy Mix PCR master mix (Thermo Fisher) using primers for FeLV p27gag F 191 
5’-CCCAGTGGCCCTAACTAACC-3’ and R 5’-GCTGGCGTTTCCTCTTTCC-3’or FeLV Pol F 5’-192 
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GCAACCGGTAAGGTGACTC-3’ and Pol R 5’-TTCAAAGGGTTTGGTGATATCTG-3’. DNA was 193 
denaturated at 94oC for 3mins then put through 35 cycles of  94oC 30s, 60oC 30s, 72oC 30s. 194 
Products were purified through Qiagen QIAquick PCR purification columns then cloned into 195 
pCR2.1-TOPO (InVitrogen), transformed into TOP10 competent cells and plated on Amp Xgal 196 
agarplates. White colonies were cultured and plasmid DNA extracted using Qiaprep spin 197 
preps and DNA was sequenced from M13 F and M13 R primers by Source BioScience and 198 
examined for mutations relative to pFGB molecular clone using Hypermut 2.0. 199 
Alu-Gag PCR 200 
Primary PCR on 50ng genomic DNA was performed in Platinum Taq DNA polymerase 201 
(Invitrogen) using 10μM primers AluF 5’-GCCTCCCAAAGTGCTGGGATTACAG-3’ and FeLV gag 202 
R 5’ –ATAGGGAGGTGGCTCTTCTG-3’ for 95oC 2 mins, then 40 cycles of 95oC 15s, 50oC 15s, 203 
72oC 3m30s.  Nested  PCR was carried out on 4μl primary pcr or 4ng unamplified DNA using  204 
FeLV RU5 F 5’-TCTTTGCTGAGACTTGACCG-3’ and FeLV RU5 R 5’-ACTAGGTCTTCCTCGGCGAT-205 
3’ and probe FeLV RU5 5’FAM-TGCATCTGACTCGTGGTCTC-TAMRA-3’ using Takyon LowRox 206 
Probe Mastermix dTTP blue (UF-LPMT-BO101) (Eurogentec)  and settings of 50oC 2 min, 207 
95oC 3min then 40 cycles 95oC 10s, 60oC 60s on ABI7500 Real Time PCR system. 208 
LTR circle detection  209 
100ng aliquots of genomic DNA from 3 day (PBMC, Reh and KYOI) or 24 hr (3201 and 210 
HEK293)  FeLV-infected cells was amplified in Reddy Mix PCR master mix with primers  211 
Circles env F 5’ TAAAACAGCGGCAACAACTG-3’ and Circles gag R 5’-212 
GTCTCCGATCAACACCCTGT-3’ or positive control pan-myc 23F 5’-213 
CCAACAGGAACTATGACCTCG-3 and 96R 5’-GTAGAAGTTCTCCTCCTCGTC-3’. Following an 214 
initial denaturation step at 94C 3 min,  35 cycles of 94oC 30s, 60oC 30s, 72oC 1m 30s were 215 
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performed. 15μl of each 25μl reaction were separated on 1.4% agarose TAE gel and 216 
visualised by staining with ethidium bromide.  217 
  218 
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RESULTS 219 
Human cells display marked differences in susceptibility to FeLV-B infection  220 
The rationale for focusing on FeLV-B as the most likely zoonotic variant is presented in 221 
Figure 1A. FeLV-B is the most commonly occurring envelope variant with human cell tropism 222 
and is formed by recombination with endogenous FeLV-related sequences (20) (Figure 1B).  223 
To generate FeLV-B virus stocks, the prototypic molecular clone of the FeLV-B Gardner-224 
Arnstein was reconstituted by transfection and propagated in HEK293 cells which release 225 
high titre FeLV-B into cell supernatants (105-6 infectious units /ml) and titrated on feline 226 
QN10S cells (36). In initial experiments it was noted that human cells in culture were 227 
invariably susceptible to virus infection, but with markedly different proviral copy numbers 228 
as assessed by Southern blot or quantitative PCR.  This phenomenon was explored further in 229 
a dilution/spreading assay where cells were exposed at decreasing multiplicities of infection 230 
(from 1 to 10-4) and cultured for two weeks to allow virus spread before harvest of cells and 231 
analysis of FeLV proviral DNA by Southern blot hybridisation. Detection of an internal 3.7kb 232 
genome fragment provides a quantitative estimate of FeLV DNA content, as shown in Figure 233 
1C.  Three distinct patterns were noted. HEK293 cells are permissive, and FeLV-B spread 234 
rapidly to saturation after low multiplicity of infection (MOI). At the other extreme, the non-235 
permissive Reh B-cell leukemia cell line showed detectable proviral DNA only at MOI=1.  The 236 
KYO-1 myeloid leukemia cell line showed an intermediate, partially permissive pattern with 237 
diminishing copy number in proportion to the infectious challenge dose.  Quantitative PCR 238 
analysis of DNA from cells infected at MOI =1 indicated thirty-fold lower levels of FeLV DNA 239 
in Reh cells (~0.3 copies/cell) compared to semi-permissive Kyo1 cells which displayed 240 
similar levels to permissive controls (~10 copies /cell).    241 
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As listed in Table 1, the infection/spread assay revealed full permissiveness (phenotype 1) 242 
for replication of FeLV-B in 7 of 11 human cancer cell lines selected from the NCI60 cancer 243 
cell panel (https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm). A smaller 244 
number of cancer cell lines were partially permissive (phenotype 2) or non-permissive 245 
(phenotype 3), with no obvious relationship to expression of receptor PIT-1 mRNA as 246 
measured by q-RT-PCR, which was in almost all cases higher than the permissive HEK293 247 
control). (Figure 1D). 248 
While the spreading phenotype 1 was observed in multiple cancer cell lines, we noted that 249 
Hs68 primary foreskin fibroblasts were more restrictive. To explore the possibility that 250 
phenotype 1 is a feature of long-established cancer cell lines we extended our study  to a 251 
panel of recently established pancreatic cancer cell lines (38) as well as other non-252 
transformed cells including non-immortalised cord blood CD34+ cells, lung fibroblasts 253 
(IMR90)  and immortalised but non-transformed skin keratinocytes (HaCAT).  Where cell 254 
numbers were limiting (e.g. for CD34+ cells), analysis of FeLV DNA content was carried out 255 
by quantitative PCR. Pancreatic cancer cell lines displayed either fully or partially permissive 256 
phenotypes, while the latter phenotype was also observed in cord blood CD34+ cells.  The 257 
fully permissive phenotype 1 was observed in HaCAT and IMR90 cells, indicating that 258 
permissiveness is not simply a consequence of oncogenic transformation. Another 259 
important point to note is that we observed no evidence of cytopathic effect or significant 260 
growth alteration in any of the FeLV-B infected cell cultures, indicating that restricted viral 261 
spread was not due to loss of cell viability or interference with cell division In contrast, FeLV-262 
C variants have marked cytopathic effects in some cells (39) 263 
Human haematopoietic cells display partially permissive or non-permissive phenotypes 264 
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The permissive spreading phenotype in multiple cancer cell lines is associated with release 265 
of high titre FeLV at levels comparable to feline fibroblast controls. To explore the basis of 266 
the restricted replication phenotypes in greater depth, we examined the expression of 267 
intracellular viral antigen and virion production in representative cell lines (KYO-1 and Reh) 268 
exposed to FeLV-B at MOI>1 and cultured for two weeks to allow viral spread. To explore 269 
the hypothesis that haematopoietic cells are more widely resistant, we extended this 270 
analysis to a wider panel of haematopoietic cell lines as well as primary human peripheral 271 
blood mononuclear cells.  As shown in Figure 2, infected KYO-1 cells express FeLV Pr65Gag 272 
precursor polyprotein at similar levels to permissive feline fibroblast cells (AH927) while Reh 273 
cells and PBMCs cells produce low or undetectable levels.  A similar divergence was noted 274 
when virion production was analysed.  At 14 days post-infection, partially permissive KYO-1 275 
cells showed sustained release of virions at similar levels to permissive feline cells, while 276 
virion release by Reh and PBMC was low to undetectable (Figure 2A).  In a separate 277 
experiment the virtual equivalence of virion protein release was illustrated by serial dilution 278 
of pelleted virion preparations prior to western blot analysis. As shown in Figure 2C and 279 
Table 2, extending this analysis to a wider panel of haematopoietic cell lines showed that 280 
nine of thirteen  leukemia cell lines displayed a KYO-1-like phenotype with sustained high 281 
level release of virions, while the other four resembled Reh cells, with very low to 282 
undetectable release of virus.  The level of permissiveness showed no clear pattern with 283 
regard to leukemia type (B-cell, T-cell, myeloid, erythroleukemia) or to cytogenetic features 284 
of the leukemia cell lines.  PBMCs from four separate donors and a series of four EBV-285 
immortalised lymphoblastoid cell lines showed low to non-permissive phenotype in this 286 
assay. Assay for infectious FeLV released by these cells revealed a similar pattern.  Not 287 
surprisingly, cells with low virion release did not release significant levels of infectious FeLV.  288 
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However, virus released at high levels from partially permissive lines showed very marked 289 
differences in specific infectivity, between 4 to 104-fold lower than virus released from 290 
permissive feline cells. The CEM cell line and its derivative CEMSS (40) were the most 291 
permissive lines tested, while Raji and LAMA84 cells released the least infectious virions 292 
(Table 2).      293 
The block to FeLV-B replication in non-permissive cells occurs after reverse transcription  294 
To explore the basis of the non-permissive phenotype in greater detail, we examined the 295 
accumulation of proviral DNA after exposure of cells to FeLV-B at MOI=1. Notably, non-296 
permissive PBMCs accumulated levels of FeLV DNA similar to those observed in partially 297 
permissive, high virion release KYO-1 cells (Figure 3A). This was not due to detection of pre-298 
existing DNA in virions, as only very low levels were detected after the 30 min adsorption 299 
period, with significant increases by 6 hrs.  To confirm that this accumulation is a receptor-300 
dependent process, we compared FeLV-A infection of permissive feline lymphoma cells 301 
(3201), to Reh cells which do not express detectable mRNA for the human receptor 302 
homologue THTR1.  This control was chosen as no PIT-1 negative cell lines were identified. 303 
The lack of accumulation of proviral DNA in the receptor negative cells supports the 304 
hypothesis that this process is the result of receptor-mediated entry.  The efficient detection 305 
of newly synthesised DNA with either LTR or envelope gene primers suggests that complete 306 
proviral sequences are present with no bias towards ’strong stop’ products (41).   307 
More extensive analysis of post-adsorption amplification of proviral DNA by quantitative 308 
PCR showed that all cells tested were initially permissive regardless of the later outcome of 309 
infection (Figure 3B).  However, comparison of the quantitative change in DNA from the 6hr 310 
time point to late infection (14 days) revealed a stark contrast between the semi-permissive, 311 
high virion release cells (e.g. , CEM, Raji, Jurkat) where copy number increased over time 312 
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and the low virion output, non-permissive cells (e.g. PBMC, Reh) which showed unchanged 313 
or decreasing levels of proviral DNA. Intriguingly, EBV-immortalised cell lines mainly fell into 314 
the partially permissive category in this assay, suggesting that significant viral spread had 315 
occurred in these cells while day 14 analysis revealed only low levels of virion release with 316 
no detectable infectivity. Again, we noted no cytopathic effect or changes in cell growth in 317 
these experiments.  318 
Integrated FeLV-B DNA persists in non-permissive human PBMCs  319 
Despite the lack of proviral DNA amplification, we noted that FeLV-B DNA was readily 320 
detectable at similar levels in PBMCs between 3 and 14 days after initial infection (Figure 321 
4A). This stable association suggested that FeLV-B DNA may be integrated in PBMCs, and 322 
this hypothesis was tested further by quantitative PCR after pre-amplification with a FeLV 323 
Gag primer and a consensus human Alu repeat sequence (Figure 4B).  The greatly enhanced 324 
detection of FeLV DNA after Alu-Gag pre-amplification indicates that much of the DNA is in 325 
integrated form.  The possibility that FeLV DNA persists in unintegrated form was also tested 326 
by PCR for circular forms generated by ligation in the nucleus.  LTR circles were barely 327 
detectable in PBMC and Reh cells by 3 days post-infection. Positive controls for this assay 328 
were early (24hr) samples from productively infected 3201 and HEK293 cells, where single 329 
and double LTR circles are detected (Figure 4C).  Cloning and sequencing confirmed the 330 
identity of the single LTR form (not shown).  331 
Partially permissive cells display G to A hypermutation that correlates with APOBEC3G 332 
mRNA expression  333 
To explore the hypothesis that APOBEC cytidine deaminase activity is involved in FeLV 334 
growth restriction we analysed proviral DNA after PCR amplification of genome fragments 335 
from infected cells.  These sequences were compared to the index FeLV-B (pFGB) sequence 336 
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for evidence of characteristic G->A mutations that are induced during reverse transcription 337 
(42). We found evidence of extensive hypermutation of FeLV replicating in human cells at 338 
rates of up to 7 mutations per kilobase. This mutation rate is much higher than the G->A 339 
mutation rate reported for FeLV replicating in cats in vivo (0.1/kb) (43), indicating that FeLV, 340 
like MLV (30) is able to evade this restriction factor only in its natural host.  FeLV strains  341 
typically encode a glycosylated Gag precursor open reading frame (44), and this is intact in 342 
the FeLV-B Gardner-Arnstein molecular clone. However FeLV, like MLV, is sensitive to 343 
heterologous human APOBEC3 activity (45).  As shown in Figure 5 with the examples of Raji 344 
Burkitt lymphoma and TKCC15LO pancreatic cancer cell line, mutational footprints indicated 345 
that the predominant signature was GG->GA, suggesting that A3G is responsible (46). 346 
Moreover, expression of A3G mRNA showed a positive correlation with mutational activity 347 
when all lines were compared (R=0.22, P=0.01).  The results are collated in Figure 5B, 348 
broken down according to permissive (phenotype 1), partially permissive (high virion 349 
release/phenotype 2) or non-permissive (phenotype 3/low virion release). Not surprisingly, 350 
permissive cells showed low A3G expression and mutational activity, while partially 351 
permissive, high virion release cells showed high A3G expression and mutational activity.  In 352 
contrast, non-permissive cells showed no evidence of hypermutation, indicating that a non-353 
mutational mechanism of resistance is operative in these cells.  Moreover, the lack of 354 
mutation in PBMCs was observed despite very high levels of A3G, suggesting that the 355 
proviral DNA detected was the result of initial reverse transcription rather than secondary 356 
spread. The four LCL lines (circled) showed significant levels of hypermutation, supporting 357 
their grouping with the partially permissive cells on the basis of proviral DNA accumulation 358 
(Figure 3).  359 
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Analysis of all G->A mutations in the cell lines with significant levels of hypermutation  360 
(Figure 5C) indicated that A3G is the major though not the sole effector of G->A mutations 361 
in the FeLV genome during replication in human cells. Notably, the two cell lines  with 362 
divergent signatures (Hs68 and KYO1) displayed high levels of APOBEC3F mRNA (not 363 
shown). The detected expression levels of A3G mRNA varied over several logs but were 364 
notably higher in cells of haematopoietic origin (Figure 5D).  The CEM cell line and it 365 
derivative CEMSS showed the lowest levels among haematopoietic cell lines, in accord with 366 
their low mutation rate and release of relatively infectious FeLV virions (Table 2). High levels 367 
of A3G relative to the HEK293 control were also associated with restricted FeLV spread in 368 
non-haematopoietic cells, but the majority of these lines showed low expression and a fully 369 
permissive phenotype.  However, as indicated in Figure 5D, the non-permissive phenotype 370 
(non-spreading phenotype 3 in Table 1 and low proviral DNA accumulation in Figure 3) 371 
shows no relationship with A3G expression or mutation rate.  Together with evidence that 372 
this arises from a post-integration block to incoming virus, it appears that this is an A3G 373 
independent block.  374 
Discussion 375 
FeLV-B strains are human cell-tropic variants that are generated frequently during FeLV 376 
infection in vivo (20, 47, 48) and are therefore of prime interest with respect to the zoonotic 377 
potential of FeLV.  This study demonstrated fully permissive or partially permissive infection 378 
in a broad range of cancer-derived cell lines and in non-transformed keratinocytes and lung 379 
fibroblasts.  Cell lines of haematopoietic origin were generally less permissive and were 380 
characterized in two discrete groups based on high or low FeLV protein expression and 381 
virion release. Primary PBMC and some EBV-transformed LCL were non-permissive with 382 
respect to these measures (Figures 1C and 2; Table 2).  While a spectrum of phenotypes was 383 
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observed, this study revealed apparently universal susceptibility of human cells to initial 384 
infection with FeLV-B, with no evidence of a significant pre-integration block to infection 385 
(Figure 4); indeed, the early steps of reverse transcription and integration appear to be 386 
unimpaired in non-permissive cells (Figures 3 and 5A-C).  However, at least two post-387 
integration blocks to FeLV-B replication appear to be operative in human cells.  One block is 388 
clearly mediated by the APOBEC system as indicated by the high rate of G->A mutations in 389 
FeLV in leukemia cell lines that release abundant viral particles with low infectivity, and in 390 
non-haematopoietic cancer cell lines that display a partially permissive phenotype with 391 
respect to viral spread (e.g., Raji and TKCC15LO, respectively; Table 2, Figures 3B and 5).  392 
The predominant mutational signature was indicative of A3G in most cases, and we noted a 393 
weak correlation between A3G mRNA expression and mutational activity across a panel of 394 
cell lines (Figure 5). This observation does not exclude the possibility that A3G also inhibits 395 
by non-mutational mechanisms such as inhibition of reverse transcription (49).   396 
The profound block to FeLV mRNA and protein expression in primary PBMC (Figure 2) and to 397 
virus release from these cells occurred without detectable mutation despite the expression 398 
of high levels of A3G mRNA (Figure 5), indicating a restriction that is A3G-independent.  399 
APOBEC3 proteins have also been reported to block incoming murine retroviruses, and it 400 
appears that ectopic expression of A3A in mice can do so by a non-mutational mechanism 401 
(45).  However, as far as we are aware, there is no evidence that APOBEC restriction can 402 
operate on incoming virus after integration.  Potential mediators of post-integration 403 
suppression of incoming viruses include epigenetic regulators such as those that are 404 
abundantly expressed in embryonal stem cells and restrict expression of exogenous and 405 
endogenous retro-elements (50).  The possibility that the resistance of PBMCs to FeLV 406 
reflects such a general resistance mechanism against gamma-retrovirus zoonosis merits 407 
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further study.  In this regard it is interesting to note reports of profound restriction of 408 
xenotropic murine leukemia virus related virus (XMRV) growth in human PBMCs which 409 
showed evidence of replication with G->A mutations only at extremely high levels of viral 410 
input (51). 411 
 With regard to relevance to zoonotic resistance, a key question is whether the widespread 412 
susceptibility to FeLV replication observed in human cells reflects the phenotype of the 413 
tissue of origin or a loss-of-function phenomenon due to oncogenic transformation.  The 414 
strongly restrictive phenotype of PBMC cultures, which contain a rich variety of primary cell 415 
types, suggests that restriction is likely to represent an important in vivo barrier. While the 416 
relative susceptibility of leukemia cell lines may be due to loss of function, the similar 417 
phenotype observed in primary CD34+ cells (Table 1) suggests that this may instead reflect 418 
an immature progenitor phenotype.   Moreover, many non-haematopoietic cell lines cells 419 
proved to be highly permissive for transcription, virion assembly and release of FeLV-B 420 
particles with no evidence of APOBEC-mediated mutations.  Observation of this phenotype 421 
in IMR90 non-transformed lung fibroblasts, for example, that retain the capacity for 422 
replicative senescence (37) as well as HaCAT skin keratinocytes shows that susceptibility to 423 
infection can occur in the absence of oncogenic transformation (Table 1). Moreover, the 424 
earliest description of productive FeLV replication in human cells was based on infection of 425 
HEL2000 primary lung fibroblasts (6).  In the case of transformed cells, it is difficult to 426 
discern whether the relative susceptibility to FeLV represents a normal cellular state 427 
relevant to potential zoonosis.  While very high level A3G expression and mutational activity 428 
was observed in the TKCC15LO pancreatic cancer cell line (Figure 5), this may not reflect the 429 
normal phenotype of pancreatic tissue. Upregulated A3G has been postulated to play a 430 
direct oncogenic role in some pancreatic cancers (52).   431 
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The susceptibility of human cancer cells to spreading FeLV-B replication provides a 432 
potentially instructive parallel with the mobilisation and frequent re-insertion of L1 433 
retrotransposons in over 50% of human cancers (53); high levels were noted in lung, colon, 434 
prostate and breast cancers while the datasets for other tumor types showed few if any new 435 
insertions in renal carcinomas and melanomas. These findings parallel the present 436 
observations in that colon, lung and breast cancer cell lines were fully permissive to FeLV 437 
infection, but renal cancer cells and one melanoma line displayed a strong early block to 438 
FeLV replication with no evidence of APOBEC-mediated mutations (Table 1, Figure 5B).  A 439 
further intriguing parallel is provided by a recent study of XMRV pathogenesis in macaques, 440 
where intravenous inoculation of high titre virus led to dissemination and persistence of 441 
viral protein expression, with highest levels in lung, colon and prostate tissues (54). Taken 442 
together, these observations suggest that susceptibility to infection may be the default state 443 
in some primary tissues. Moreover, susceptibility to FeLV may provide a useful marker to aid 444 
the identification of further factors that confer tissue-specific susceptibility to genome 445 
instability in cancer as well as resistance to incoming retroviruses.   446 
Can the risk of zoonotic infection with FeLV be discounted? Despite control measures 447 
including vaccination that have reduced the prevalence of FeLV in some parts of the world, 448 
this virus family remains one of the most important pathogens of cat species worldwide 449 
(55). Moreover, the limited barriers protecting human cells against FeLV infection contrasts 450 
with the plethora of restriction factors that protect against cross-species transmission of 451 
primate lentiviruses where recent jumps have occurred (56).  The successful transfer of 452 
other gamma-retroviruses that use PIT-1 as an entry receptor from rodents to primates (5) 453 
argues that future adaptation of FeLV for zoonotic spread is not beyond the repertoire of 454 
this virus family. The possibility of human exposure to high doses of FeLV analogous to those 455 
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employed in recent primate challenge experiments with XMRV  (54, 57) is extremely 456 
unlikely; however, it may be interesting to revisit the apparent lack of adaptive immune 457 
responses in exposed individuals, e.g. veterinary workers, (10) using more sensitive 458 
techniques.   459 
 460 
 461 
 462 
 463 
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FIGURE LEGENDS 479 
Figure 1 480 
The rationale for focus on FeLV-B as the most likely zoonotic agent is depicted in panel A. 481 
Panel B shows the outline molecular structure of FeLV-B proviruses that are derived by 482 
recombination between FeLV-A and endogenous FeLV-related proviruses in the feline 483 
genome and the origin of hybridisation probes (exU3, EnvB) used to detect FeLV sequences 484 
in human cells .  Panel C shows the three basic patterns of susceptibility of cultured human 485 
cells to infection with FeLV-B.  Cells were exposed to FeLV-B at varying multiplicity of 486 
infection and passaged for 14 days before extraction of high molecular weight DNA and 487 
analysis of FeLV proviral DNA content by Southern blot hybridisation of Kpn1 digested DNA 488 
with the exU3 probe.  Panel D shows the relative expression of mRNA encoding the FeLV-B 489 
receptor PIT-1 in a panel of cell lines sorted by pattern of FeLV-B spread. 490 
 491 
Figure 2 492 
Human haematopoietic cells display two patterns of susceptibility to FeLV-B replication. As 493 
shown in panel A, western blot analysis of intracellular Gag precursor protein (Pr65Gag) in 494 
FeLV-B infected partially permissive (phenotype 2) KYO-1 cells shows similar levels of 495 
expression to fully permissive feline fibroblast cells (AH927).  In contrast, expression of 496 
Pr65Gag is barely detectable in non-permissive Reh cells and human PBMCs.  This pattern is 497 
reflected in release of virus particles which is similar in partially permissive KYO-1 cells and 498 
permissive AH927 cells as illustrated by western blot analysis of pelleted virion preparations 499 
from equal volumes of culture medium. Panel B shows a separate experiment where 500 
western blot analysis of serial 2-fold dilutions of virions released from AH927 and KYO-1 501 
cells again showed level of particle release from KYO-1 cells within a similar range to AH927 502 
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cells. Figure 2C shows western blot analysis of pelleted virions harvested from cells 14 days 503 
after infection with FeLV-B. Equal volumes of cell supernatant (2ml) were sampled 24 hours 504 
after medium change and processed as described in Methods.  505 
Figure 3 506 
Permissive and non-permissive human cells support FeLV-B entry and early proviral DNA 507 
synthesis at similar levels.  As shown in panel A, initial studies using standard PCR using 508 
primers based on FeLV LTR or envelope sequences  showed marked increases in proviral 509 
DNA between 0.5 and 6 hours after exposure of cells to FeLV-B at MOI=1.  As no PIT-1 510 
negative cell lines were identified, a receptor-negative control was generated for this assay 511 
by comparing FeLV-A infection of permissive feline cells (3201) and Reh cells that lack 512 
detectable expression of mRNA for the FeLV-A receptor human homologue THTR1.  Loading 513 
controls used human GAPDH or pan-myc primers which efficiently detects human and feline 514 
DNA A wider analysis of FeLV-B infection of human haematopoietic cell lines is shown in 515 
panel B where proviral DNA levels were analysed by quantitative PCR.  The line charts show 516 
changes in FeLV DNA concentration (detected by EnvB primers) compared to a 517 
housekeeping gene control (albumin) between 0.5 and 6 hrs (top panels) or 6hrs and 14 518 
days (lower panels) after infection. The y axis shows the Ct value relative to albumin control 519 
(=0). Partially permissive cells were CEM, Jurkat and Raji.  Non-permissive cells were PBMC 520 
(n=2), Reh and ALL/MIK.  Lymphoblastoid cells lines were LCL30, 98, 113 and 114.  521 
Figure 4 522 
Persistence of integrated FeLV-B DNA in human PBMC. As shown in panel A, semi-523 
quantitative PCR reveals dose-dependent persistence of FeLV DNA in human PBMCs at 14 524 
days post-infection. Fully permissive HEK293 control cells show stable levels by 3 days post-525 
infection.  Panel B shows the results of quantitative PCR time course analysis for FeLV 526 
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sequences in PBMC DNA, with and without a pre-amplification step using primers to FeLV 527 
Gag and consensus human Alu sequences.  The Ct value (threshold cycle number) is 528 
inversely proportional to DNA content. Panel C shows the results of semi-quantitative PCR 529 
for LTR circles in FeLV-B infected cells 3 days (PBMC, Reh, KYO-1) or 24 hours (3201, 530 
HEK293) after infection.   While single and double LTR circle forms are readily detected in 531 
productively infected HEK293 and 3201 cells, they are barely detectable in Reh and PBMC 532 
relative to permissive HEK293 control cells. The loading control was provided by PCR 533 
amplification with conserved Myc primers (pan-Myc). 534 
Figure 5 535 
Hypermutation of the FeLV-B genome and APOBEC3G mRNA expression in human cells. 536 
FeLV genomic sequences (segments of Gag and Pol) were cloned by PCR from infected 537 
human cells and individual templates were sequenced and compared to the reference input 538 
virus (pFGB clone). APOBEC3G mRNA expression was determined in the same cells (prior to 539 
infection) by quantitative real time PCR (SYBR green). Panel A shows representative plots of 540 
hypermutation visualised by online HYPERMUT programme 541 
(www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html) where sequence changes 542 
relative to the reference FeLV-B genome are colour coded (red: GG->AG; cyan:GA-543 
>AA;green:GC->AC;magenta:GT->AT;black:nonG->A). 544 
Panel B shows X/Y plots of G->A mutation (/kb) against APOBEC3G mRNA level (1=HEK293) 545 
with cell lines sorted according to FeLV restriction phenotype. LCL lines that are discordant 546 
by their low infectious virion release (Table 2) but post-infection accumulation of proviral 547 
DNA (Figure 3) are highlighted by a dotted circle. Panel C the percentage of G->A mutations 548 
that conform to the A3G signature (46) for all lines in which significant levels of mutations 549 
were detected. Blue grey bars : haematopoietic cells, yellow bars: non-haematopoietic cells. 550 
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Panel D shows the relative levels of APOBEC3G mRNA (log10 scale; HEK293=1) for all the cell 551 
lines tested, sorted into haematopoietic (blue circles) and non-haematopoietic (green 552 
circles). Non-permissive cells (non-spreading and low virion release) are denoted by black 553 
circles. 554 
  555 
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